Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research
On this page...
Tram Kim Lam, Ph.D., M.P.H.
Program Director, Environmental Epidemiology Branch
lamt@mail.nih.gov
Phil Daschner, M.Sc.
Program Director, Division of Cancer Biology
daschnep@mail.nih.gov
Edward Sauter, M.D., Ph.D.
Medical and Program Officer, Breast and Gynecologic Cancer Research Group (BGCRG), Division of Cancer Prevention
edward.sauter@nih.gov
Overview
The overall purpose of NCI’s Metabolic Dysregulation and Cancer Risk Program is to enhance knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk in individuals and identify mechanisms that will enhance cancer risk prediction, screening for high-risk individuals in clinical settings, and potential targets for preventive and therapeutic interventions.
For the purposes of the funding opportunities that will support this research, metabolic dysregulation is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism.
This program will be supported by two funding opportunity announcements (FOAs): one will support multiple research project grants and another will support a coordinating center.
Funding Opportunities
NCI-sponsored Funding Opportunity Announcements (FOAs) related to metabolic dysregulation and risk of cancer include:
- Metabolic Dysregulation and Cancer Risk Program, Research Grants: A Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) – expires October 7, 2021
- Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Research (U24 Clinical Trial Not Allowed) – expires October 7, 2021
Pre-Application Webinar
- Pre-application Webinar for Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research - RFA-CA-21-021 and RFA-CA-21-022 (August 2021)
